Exact Mass: 331.0951

Exact Mass Matches: 331.0951

Found 60 metabolites which its exact mass value is equals to given mass value 331.0951, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

R-95913

1-cyclopropyl-2-(2-fluorophenyl)-2-{2-hydroxy-4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}ethan-1-one

C18H18FNO2S (331.1042)


R-95913 is only found in individuals that have used or taken Prasugrel. R-95913 is a metabolite of Prasugrel. R-95913 belongs to the family of Thienopyridines. These are heterocyclic compounds containing a thiophene ring fused to a pyridine ring.

   

5'-O-Desmethyl omeprazole

2-[(4-Methoxy-3,5-dimethylpyridin-2-yl)methanesulphinyl]-1H-1,3-benzodiazol-6-ol

C16H17N3O3S (331.0991)


5-O-Desmethyl omeprazole is only found in individuals that have used or taken Omeprazole. 5-O-Desmethyl omeprazole is a metabolite of Omeprazole. 5-o-desmethyl omeprazole belongs to the family of Sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.

   

(R)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

2-amino-3-(benzylsulfanyl)-N-(4-nitrophenyl)propanamide

C16H17N3O3S (331.0991)


   

Didesethylflurazepam

1-(2-aminoethyl)-7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

C17H15ClFN3O (331.0888)


   
   

O1-[(3,5-Dimethylisoxazol-4-yl)carbonyl]-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanehydroximamide

O1-[(3,5-Dimethylisoxazol-4-yl)carbonyl]-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanehydroximamide

C12H12F3N5O3 (331.0892)


   
   
   
   
   

Euxylophoricine C

Euxylophoricine C

C19H13N3O3 (331.0957)


   
   

Isofenphos-methyl

Isofenphos-methyl

C14H22NO4PS (331.1007)


   

Z-Phe-chloromethylketone

Z-Phe-chloromethylketone

C18H18ClNO3 (331.0975)


   

MY-5445

1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl-

C20H14ClN3 (331.0876)


MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a Ki of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect[1][2].

   

zpck

1-BENZYLOXYCARBONYLAMINOPHENETHYL CHLOROMETHYL KETONE

C18H18ClNO3 (331.0975)


   

R-95913

1-cyclopropyl-2-(2-fluorophenyl)-2-{2-hydroxy-4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}ethan-1-one

C18H18FNO2S (331.1042)


   

5-O-Desmethyl omeprazole

2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazol-6-ol

C16H17N3O3S (331.0991)


   

7-chloro-4-(4-methylpiperazin-1-yl)-10H-thieno[3,2-c][1]benzazepine

7-chloro-4-(4-methylpiperazin-1-yl)-10H-thieno[3,2-c][1]benzazepine

C17H18ClN3S (331.091)


   

CBZ-S-Phenyl-L-Cysteine

CBZ-S-Phenyl-L-Cysteine

C17H17NO4S (331.0878)


   

4-[2-[[(4-Methylphenyl)sulfonyl]oxy]ethyl]-1,3-dihydro-2H-indole-2-one

4-[2-[[(4-Methylphenyl)sulfonyl]oxy]ethyl]-1,3-dihydro-2H-indole-2-one

C17H17NO4S (331.0878)


   

4-(ISOCYANO(TOSYL)METHYL)-1,2-DIMETHOXYBENZENE

4-(ISOCYANO(TOSYL)METHYL)-1,2-DIMETHOXYBENZENE

C17H17NO4S (331.0878)


   

4-Hydroxy Omeprazole

4-Hydroxy Omeprazole

C16H17N3O3S (331.0991)


   

3,4,6-TRI-O-ACETYL-2-AZIDO-2-DEOXY-D-GALACTOSE

3,4,6-TRI-O-ACETYL-2-AZIDO-2-DEOXY-D-GALACTOSE

C12H17N3O8 (331.1016)


   

5-(2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2(4H)-one

5-(2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2(4H)-one

C18H18FNO2S (331.1042)


   

2-(TETRAHYDRO-FURAN-2-YL)-N-(3-TRIFLUOROMETHYL-PHENYL)-SUCCINAMIC ACID

2-(TETRAHYDRO-FURAN-2-YL)-N-(3-TRIFLUOROMETHYL-PHENYL)-SUCCINAMIC ACID

C15H16F3NO4 (331.1031)


   

2-(2-FLUOROACETAMIDO)-5-NITRO-N-(O-TOLYL)BENZAMIDE

2-(2-FLUOROACETAMIDO)-5-NITRO-N-(O-TOLYL)BENZAMIDE

C16H14FN3O4 (331.0968)


   

1-((3-ETHYL-2(3H)-BENZOTHIAZOLYLIDENE)-&

1-((3-ETHYL-2(3H)-BENZOTHIAZOLYLIDENE)-&

C21H17NOS (331.1031)


   

5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-3,4,6,7-tetrahydrothieno[3,2-c]pyridin-2-one

5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-3,4,6,7-tetrahydrothieno[3,2-c]pyridin-2-one

C18H18FNO2S (331.1042)


   

norfluoxetine hydrochloride

norfluoxetine hydrochloride

C16H17ClF3NO (331.0951)


Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity[1][2][3][4].

   

1-Benzyl-7-phenyl-1H-pyrimido[4,5-d][1,3]oxazine-2,4-dione

1-Benzyl-7-phenyl-1H-pyrimido[4,5-d][1,3]oxazine-2,4-dione

C19H13N3O3 (331.0957)


   

tert-butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate

tert-butyl 4-(2,6-dichloropyridin-4-yl)piperazine-1-carboxylate

C14H19Cl2N3O2 (331.0854)


   

Warfarin sodium

Warfarin sodium

C19H16NaO4 (331.0946)


   

2-METHYL-5-PHENYL-3-(3-SULFOPROPYL)BENZOXAZOLIUM HYDROXIDE, INNER SALT

2-METHYL-5-PHENYL-3-(3-SULFOPROPYL)BENZOXAZOLIUM HYDROXIDE, INNER SALT

C17H17NO4S (331.0878)


   

4-{5-[(2-Chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride (1:1)

4-{5-[(2-Chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride (1:1)

C14H19Cl2N3O2 (331.0854)


   

S-BENZYL-L-CYSTEINE-4-NITROANILINE

(R)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

C16H17N3O3S (331.0991)


   

(Z)-N-[(5-Chloro-2-hydroxyphenyl)(phenyl)methylene]-L-valine

(Z)-N-[(5-Chloro-2-hydroxyphenyl)(phenyl)methylene]-L-valine

C18H18ClNO3 (331.0975)


   

(R)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE HYDROCHLORIDE

(R)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE HYDROCHLORIDE

C16H17ClF3NO (331.0951)


   

diethyl 2-[[4-(trifluoromethyl)anilino]methylidene]propanedioate

diethyl 2-[[4-(trifluoromethyl)anilino]methylidene]propanedioate

C15H16F3NO4 (331.1031)


   

5-(((Carboxymethyl)amino)methyl)uridine

5-(((Carboxymethyl)amino)methyl)uridine

C12H17N3O8 (331.1016)


   

(S)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

(S)-2-Amino-3-benzylthio-N-(4-nitrophenyl)propionamide

C16H17N3O3S (331.0991)


   

Carbamimidothioic acid 2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl ester

Carbamimidothioic acid 2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl ester

C16H17N3O3S (331.0991)


   

4-amino-6,7-diphenyl-2(1H)-pteridinethione

4-amino-6,7-diphenyl-2(1H)-pteridinethione

C18H13N5S (331.0892)


   

3-phenyl-4-[[4-(trifluoromethyl)anilino]methylidene]-1H-pyrazol-5-one

3-phenyl-4-[[4-(trifluoromethyl)anilino]methylidene]-1H-pyrazol-5-one

C17H12F3N3O (331.0932)


   

2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid

2-[(Phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid

C17H17NO4S (331.0878)


   

5-Carboxymethylaminomethyluridine

5-Carboxymethylaminomethyluridine

C12H17N3O8 (331.1016)


   

N-{4-[N-(phenylsulfonyl)ethanehydrazonoyl]phenyl}acetamide

N-{4-[N-(phenylsulfonyl)ethanehydrazonoyl]phenyl}acetamide

C16H17N3O3S (331.0991)


   

4-[5-(3-Hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile

4-[5-(3-Hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile

C19H13N3O3 (331.0957)


   

2-[[(4-Tert-butylphenyl)-oxomethyl]amino]-4-chlorobenzoic acid

2-[[(4-Tert-butylphenyl)-oxomethyl]amino]-4-chlorobenzoic acid

C18H18ClNO3 (331.0975)


   

4-[(5Z)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]butanoic acid

4-[(5Z)-5-[(Z)-2-methyl-3-phenylprop-2-enylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]butanoic acid

C17H17NO4S (331.0878)


   

Didesethylflurazepam

Didesethylflurazepam

C17H15ClFN3O (331.0888)


A primary amino compound resulting from the dealkylation of both ethyl groups of the anti-insomnia drug flurazepam. It is the major metabolite of flurazepam.

   

5-O-Desmethyl Omeprazole

5-O-Desmethyl Omeprazole

C16H17N3O3S (331.0991)


   

1-cyclopropyl-2-(2-fluorophenyl)-2-{2-hydroxy-4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}ethan-1-one

1-cyclopropyl-2-(2-fluorophenyl)-2-{2-hydroxy-4H,5H,6H,7H-thieno[3,2-c]pyridin-5-yl}ethan-1-one

C18H18FNO2S (331.1042)


   

GAC0001E5

GAC0001E5

C17H12F3N3O (331.0932)


GAC0001E5 is an LXR inverse agonist. GAC0001E5 has antiproliferative activity and can be used in cancer research[1].

   

SW157765

SW157765

C19H13N3O3 (331.0957)


SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs[1][2].

   

10,11,12,13-tetrahydroxy-11-(hydroxymethyl)-6-imino-3-oxa-5,7-diazatetracyclo[7.4.0.0¹,⁴.0⁴,⁸]tridecane-2-carboxylic acid

10,11,12,13-tetrahydroxy-11-(hydroxymethyl)-6-imino-3-oxa-5,7-diazatetracyclo[7.4.0.0¹,⁴.0⁴,⁸]tridecane-2-carboxylic acid

C12H17N3O8 (331.1016)


   

4-[(6-hydroxyphenazin-1-yl)amino]benzoic acid

4-[(6-hydroxyphenazin-1-yl)amino]benzoic acid

C19H13N3O3 (331.0957)


   

7-[(4-hydroxy-3-nitrophenyl)methyl]-1,3-dimethylpurine-2,6-dione

7-[(4-hydroxy-3-nitrophenyl)methyl]-1,3-dimethylpurine-2,6-dione

C14H13N5O5 (331.0917)


   

18,20-dioxa-3,13,24-triazahexacyclo[11.11.0.0²,¹⁰.0⁴,⁹.0¹⁵,²³.0¹⁷,²¹]tetracosa-1(24),2(10),4,6,8,15,17(21),22-octaen-14-one

18,20-dioxa-3,13,24-triazahexacyclo[11.11.0.0²,¹⁰.0⁴,⁹.0¹⁵,²³.0¹⁷,²¹]tetracosa-1(24),2(10),4,6,8,15,17(21),22-octaen-14-one

C19H13N3O3 (331.0957)


   

6-hydroxy-5,10-dimethyl-5,10,19-triazapentacyclo[10.7.1.0²,⁷.0⁹,²⁰.0¹³,¹⁸]icosa-1,3,6,9(20),12,14,16,18-octaene-8,11-dione

6-hydroxy-5,10-dimethyl-5,10,19-triazapentacyclo[10.7.1.0²,⁷.0⁹,²⁰.0¹³,¹⁸]icosa-1,3,6,9(20),12,14,16,18-octaene-8,11-dione

C19H13N3O3 (331.0957)